Scientists identify natural defence cells that impede chemotherapy treatment

As part of the body’s front-line defences against infection, white blood cells called macrophages often infiltrate tumours in great numbers. However, according to new research published in the scientific journal Cancer Discovery, these cells can make tumours more resistant to chemotherapy treatment.

The international team of scientists involved in the discovery have shown that a depletion of macrophages (TAM) in progressing breast tumours improved the anti-tumour effectiveness of paclitaxel, a chemotherapeutic agent.

When the team treated TAM-depleted tumours (which also had fewer blood vessels, greater numbers of cytotoxic T and more signs of tumour destruction) with paclitaxel they witnessed a greater reduction in the size of the tumour.

“Our findings offer a new approach to improving the efficacy of established agents,” said Dr Donal Brennan from the UCD Conway Institute, who, along with his UCD colleague Professor William Gallagher, was part of the international team led by Professor Lisa Coussens from the University of California San Francisco.

“In addition to identifying a novel therapeutic agent, we have also developed a predicitive inflammatory signature which will identify patients likely to respond to anti-CSF1R therapy,” said Dr Brennan.

“The inflammatory signature will hopefully allow us to run biomarker driven clinical trials, which should allow for rapid translation of these findings into breast cancer clinics over the next few years.”

Commenting on the significance of the findings, a news article in the leading scientific journal Nature said: these results “add weight to an emerging compelling case for deciphering the complexity of leukocyte infiltrates in breast cancer.” And, “this may provide clinically relevant indications of the likely response to chemotherapy and thus patient survival.”

The predicitive signature developed during this research project took advantage of a novel image analysis approach, IHC-MARK, developed by Professor Gallagher’s team at the UCD Conway Institute, to quantify inflammatory cell density in cancer tissues. The method is currently being in-licenced to the spin-out company, OncoMark Limited, which is utilising such automated image analysis approaches for development of companion diagnostics.

More information: “Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy” published in Cancer Discovery. David G. DeNardo; Donal J Brennan, Elton Rexhepaj; Brian Ruffell; Stephen L. Shiao; Stephen F. Madden; William M Gallagher, Nikhil Wadhwani; Scott D. Keil; Sharfaa A. Junaid; Hope S. Rugo; E. Shelley Hwang; Karin Jirstrom; Brian L. West; and Lisa M. Coussens.

Provided by University College Dublin

1 /5 (1 vote)

Related Stories

Genes associated with aggressive breast cancer

Aug 16, 2010

Researchers at the University of Gothenburg, Sweden, have for the first time identified 12 genes that could be associated with aggressive breast tumours. The discovery could result in more reliable prognoses and better treatment ...

Innovative method to starve tumors

Feb 11, 2009

The development of cancerous tumours is highly dependent on the nutrients the tumours receive through the blood. The team of Dr. Janusz Rak, of the Research Institute of the McGill University Health Centre (MUHC) at the Montreal ...

Recommended for you

US OKs first-ever DNA alternative to Pap smear (Update 2)

5 hours ago

U.S. government health regulators have cleared a genetic test from Roche as a first-choice screening option for cervical cancer. It was a role previously reserved for the Pap smear, the decades-old mainstay of women's health.

New breast cancer imaging method promising

11 hours ago

The new PAMmography method for imaging breast cancer developed by the University of Twente's MIRA research institute and the Medisch Spectrum Twente hospital appears to be a promising new method that could ...

Palliation is rarely a topic in studies on advanced cancer

12 hours ago

End-of-life aspects, the corresponding terminology, and the relevance of palliation in advanced cancer are often not considered in publications on randomized controlled trials (RCTs). This is the result of an analysis by ...

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

Sepp
not rated yet Apr 29, 2011
I'd like to know what is good about knocking out the body's immune defenses OR about poisoning a tumor and with it, the host body.

Does anyone see the utter senselessness of this approach?